Search
LY-517717
go.drugbank.com/drugs/DB05713InvestigationalLY517717 is an investigational oral direct inhibitor of activated Factor Xa. It is believed to be Lilly's PMD-3112 (licensed from Amgen).
Gaboxadol
go.drugbank.com/drugs/DB06554InvestigationalDevelopment of Gaboxadol was stopped in March 2007 after concerns regarding safety and efficacy. It acts on the GABA system, but in a seemingly different way from benzodiazepines and other sedatives. … Gaboxadol also known as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP) is an experimental sleep aid drug developed by Lundbeck and Merck, who reported increased deep sleep without the reinforcing
Omarigliptin
go.drugbank.com/drugs/DB11992InvestigationalOmarigliptin has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Chronic Renal Insufficiency.
Categories: DPP-IV InhibitorsIR208
go.drugbank.com/drugs/DB05106InvestigationalIt contains three peptides (BV5S2, BV6S5 and BV13S1) expressed by T-Cells in over 90% of MS patients. IR208 is currently undergoing Phase II studies in a 200-patient trial. … IR208 is a synthetic T-Cell receptor peptide vaccine developed by Immune Response Corporation.
Rabeximod
go.drugbank.com/drugs/DB05772InvestigationalRabeximod is an orally administered compound for treatment of moderate or severe active rheumatoid arthritis that is currently undergoing phase II clinical testing in eight European countries.
Octylphenoxy polyethoxyethanol
go.drugbank.com/drugs/DB04682ExperimentalCategories: Compounds used in a research, industrial, or household settingTetramethrin
go.drugbank.com/drugs/DB13752ExperimentalCategories: Compounds used in a research, industrial, or household settingFenvalerate
go.drugbank.com/drugs/DB18391ExperimentalCategories: Compounds used in a research, industrial, or household settingFolitixorin calcium
go.drugbank.com/drugs/DB05308InvestigationalCoFactor use with 5-FU is being evaluated in clinical trials in first line treatment of metastatic colorectal cancer. … ANX-510 (CoFactor) is a folate-based biomodulator drug being developed to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapy, 5-fluorouracil (5-FU).